Search

Your search keyword '"K. Zeilinger"' showing total 94 results

Search Constraints

Start Over You searched for: Author "K. Zeilinger" Remove constraint Author: "K. Zeilinger"
94 results on '"K. Zeilinger"'

Search Results

51. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor.

52. Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

53. Perfusion circuit concepts for hollow-fiber bioreactors used as in vitro cell production systems or ex vivo bioartificial organs.

54. Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies.

55. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project.

56. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.

57. Optimization of a serum-free culture medium for mouse embryonic stem cells using design of experiments (DoE) methodology.

58. Molecular characterization of cultured adult human liver progenitor cells.

59. Three-dimensional perfusion bioreactor culture supports differentiation of human fetal liver cells.

60. Lidocaine/monoethylglycinexylidide test, galactose elimination test, and sorbitol elimination test for metabolic assessment of liver cell bioreactors.

61. Feasibility of using sodium chloride as a tracer for the characterization of the distribution of matter in complex multi-compartment 3D bioreactors for stem cell culture.

62. Dynamic 3D culture promotes spontaneous embryonic stem cell differentiation in vitro.

63. Interwoven four-compartment capillary membrane technology for three-dimensional perfusion with decentralized mass exchange to scale up embryonic stem cell culture.

64. The Characterization Tool: A knowledge-based stem cell, differentiated cell, and tissue database with a web-based analysis front-end.

65. Isolation and characterization of adult human liver progenitors from ischemic liver tissue derived from therapeutic hepatectomies.

66. Effect of human patient plasma ex vivo treatment on gene expression and progenitor cell activation of primary human liver cells in multi-compartment 3D perfusion bioreactors for extra-corporeal liver support.

67. Evaluation and optimization of hepatocyte culture media factors by design of experiments (DoE) methodology.

68. Bioartificial liver systems: why, what, whither?

69. Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways.

70. Evaluation of primary human liver cells in bioreactor cultures for extracorporeal liver support on the basis of urea production.

71. Dynamics of amino acid metabolism of primary human liver cells in 3D bioreactors.

72. Time course of primary liver cell reorganization in three-dimensional high-density bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study.

73. Extracorporeal liver support based on primary human liver cells and albumin dialysis--treatment of a patient with primary graft non-function.

74. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells.

75. Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study.

76. Recovery of preservation-injured primary human hepatocytes and nonparenchymal cells to tissuelike structures in large-scale bioreactors for liver support: an initial transmission electron microscopy study.

77. Primary human liver cells as source for modular extracorporeal liver support--a preliminary report.

78. Extracorporeal liver support: porcine or human cell based systems?

79. Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions.

81. Large-scale isolation of sinusoidal endothelial cells from pig and human liver.

82. The suitability of hepatocyte culture models to study various aspects of drug metabolism.

83. [Liver cell culture in bioreactors for in vitro drug studies as an alternative to animal testing].

84. Local liberation of cytokines during liver preservation.

85. A second native renal allograft of donor origin in a model of chronic rejection demonstrates improved long-term function.

86. Cell detachment during sinusoidal reperfusion after liver preservation: an in vitro model.

87. Chronically rejected rat kidney allografts induce donor-specific tolerance.

88. Visualization of liver sinusoidal endothelial cell repair behavior after preservation by in vitro time-lapse video microscopy.

89. Effect of energy substrates on the preservation outcome of hepatocytes and sinusoidal endothelial cells in an experimental hypoxia/reoxygenation model.

90. Membrane proteins.

91. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site.

92. Binding of lymphocytes to acutely rejecting rat kidney allografts in vitro is guided by events in the graft itself rather than by sensitization of host lymphocytes.

93. High-performance capillary electrophoresis of hydrophobic membrane proteins.

94. Preparative isolation of glycoproteins from plasma membranes of different rat organs.

Catalog

Books, media, physical & digital resources